EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)

Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials

Denzel Zhu iD, Matthew Steidle, Yufei Jia, Zijing Cheng, Brendan J Guercio iD, Jathin Bandari, Kamil Malshy

Cancer · 2026

DOI: 10.1002/cncr.70480 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2026. Verfasst von Denzel Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Rochester Medical Center, Rochester, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Hyperphosphatemia, Protein Kinase Inhibitors, Pyrazoles. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperphosphatemia is a recognized on‐target adverse event of erdafitinib, a pan–fibroblast growth factor receptor (pan‐FGFR) tyrosine kinase inhibitor with Food and Drug Administration approval to treat advanced urothelial cell carcinoma with FGFR2/3 mutations. This study hypothesized that hyperphosphatemia is a biomarker for drug activity and is associated with improved overall survival (OS) and other oncologic end points in phase 2/3 clinical trials.

Methods

Data from the phase 2 BLC2001 and cohorts 1 and 2 of the phase 3 THOR clinical trials were pooled; only patients who received erdafitinib were included. Kaplan–Meier and Cox proportional hazards models were used to examine the effect of hyperphosphatemia (as classified by Common Terminology Criteria for Adverse Events [CTCAE] grade) on OS, progression‐free survival (PFS), and objective response rate (ORR).

Results

A total of 409 subjects (median age, 66 years; interquartile range, 60–72 years) who met the inclusion criteria were pooled from the THOR and BLC2001 clinical trials, of whom 78.4% had hyperphosphatemia. Subjects with CTCAE grade 3+ hyperphosphatemia had improved OS (hazard ratio [HR], 0.21; 95% CI, 0.05–0.86; p = .031) and PFS (HR, 0.16; 95% CI, 0.04–0.67; p = .012) in multivariable Cox proportional hazards models compared to patients without hyperphosphatemia.

Conclusions

In this secondary analysis of the BLC2001 and THOR trials, higher CTCAE hyperphosphatemia grades were associated with improved OS, PFS, and ORR. These findings suggest that hyperphosphatemia may serve as a potential biomarker of erdafitinib activity, and warrant prospective validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellHyperphosphatemiaProtein Kinase InhibitorsPyrazolesQuinoxalinesAgedFemaleHumansMaleMiddle AgedReceptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3

Stichwörter der Autor:innen

erdafitinibfibroblast growth factor receptorhyperphosphatemiaoverall survivalurothelial carcinoma

Substanzen

erdafitinibFGFR2 protein, humanFGFR3 protein, humanProtein Kinase InhibitorsPyrazolesQuinoxalinesReceptor, Fibroblast Growth Factor, Type 2Receptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.
  • Department of Public Health Sciences, University of Rochester Medical Center, Rochester, New York, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
  • Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA.

ORCID-Profile: Denzel Zhu, Brendan J Guercio

Zitieren

APA

Zhu, D., Steidle, M., Jia, Y., Cheng, Z., Guercio, B. J., Bandari, J., & Malshy, K. (2026). Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials. Cancer. https://doi.org/10.1002/cncr.70480

Vancouver

Zhu D, Steidle M, Jia Y, Cheng Z, Guercio BJ, Bandari J, et al. Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials. Cancer. 2026. doi:10.1002/cncr.70480

BibTeX
@article{Zhu2026,
  author = {Zhu, Denzel and Steidle, Matthew and Jia, Yufei and Cheng, Zijing and Guercio, Brendan J and Bandari, Jathin and Malshy, Kamil},
  title = {Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70480}
}
Kostenlos starten →